Construction and Biological Evaluation of [177Lu]Lu-Labeled RGD/FA Dual-Targeted Lipid Nanoparticles for Tumor Imaging and Potential Theranostic Applications
Pharmaceutics · 16.11.2026 · 18 (11) · 1482
DOI: 10.3390/pharmaceutics18111482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 16.11.2026. Verfasst von Haozhan Xie und 7 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Institute of Atomic Energy, the Director Fund Project of China Institute of Atomic Energy.
Abstract (Originalsprache)
Background
The development of precision tumor theranostics necessitates a delivery platform that integrates favorable biocompatibility, effective tumor targeting, and imageable traceability. Lipid nanoparticles (LNPs) are distinguished by their favorable biocompatibility, versatile modifiability, and robust drug delivery capacity. The incorporation of multiple tumor-targeting ligands is a promising strategy to enhance the specific accumulation of nanomedicines in tumor tissues. Arginine-glycine-aspartic acid (RGD) peptides specifically recognize integrin αvβ3, while folic acid (FA) targets the folate receptor (FR), both of which are overexpressed on various tumor cells and tumor neovasculature. In this study, we developed 177Lu-labeled RGD/FA dual-targeted LNPs and systematically evaluated their physicochemical properties, radiolabeling performance, and tumor-targeting characteristics.
Methods
LNPs were fabricated via the thin-film hydration method, with RGD and FA ligands conjugated to the nanoparticle surface. The macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was incorporated to enable subsequent radiolabeling with 177Lu through a post-labeling strategy. The resulting nanoparticles were characterized for particle size, polydispersity index (PDI), zeta potential, morphology, and colloidal stability. Radiolabeling yield, radiochemical purity, and labeling stability were determined by instant thin-layer chromatography (ITLC). Cellular uptake of 177Lu-labeled dual-targeted LNPs was assessed using 4T1 murine breast carcinoma cells, and receptor-mediated targeting specificity was evaluated via blocking assays using free RGD, free FA, or a combination of both. In vivo tumor targeting and biodistribution were further investigated by micro-single-photon emission computed tomography (microSPECT/CT) imaging and ex vivo tissue distribution studies in 4T1 tumor-bearing mice.
Results
The as-prepared RGD/FA dual-targeted LNPs exhibited a mean hydrodynamic diameter of approximately 100 nm, with narrow size distribution and satisfactory colloidal stability. After 177Lu labeling, the radiolabeling yield reached 90%, and the radiochemical purity exceeded 96% following purification, with favorable radiostability over time. In vitro cellular uptake studies demonstrated that the 177Lu-labeled dual-targeted LNPs achieved the highest uptake of up to 25% AD/105 cells (AD%: percentage absorbed dose). Upon blocking with RGD or FA alone, cellular uptake was partially reduced; notably, combined blockade of both RGD- and FA-mediated pathways resulted in a maximum reduction of approximately 80% compared with the non-blocked group, consistent with the cellular internalization of the dual-targeted LNPs being predominantly mediated by receptor-specific interactions. Cytotoxicity evaluation via the Cell Counting Kit-8 (CCK-8) assay revealed that unlabeled LNPs did not induce significant cytotoxicity, with cell viability maintained at 90% ± 3.50% after 12 h of incubation with 4T1 cells. In vivo microSPECT/CT imaging revealed pronounced radioactive accumulation of 177Lu-labeled RGD/FA dual-targeted LNPs at the tumor site, concomitant with moderate uptake in the liver and spleen. Quantitative biodistribution analysis showed a time-dependent increase in tumor uptake, reaching 12.22% ± 1.22% injected dose per gram of tissue (%ID/g) at 12 h post-injection. The tumor-to-blood ratio (T/B) and tumor-to-muscle ratio (T/M) at 12 h were determined to be 2.69 and 4.35, respectively.
Conclusions
Collectively, this study successfully constructed 177Lu-labeled RGD/FA dual-targeted LNPs with favorable physicochemical properties and radiolabeling characteristics. In vitro assays confirmed the potent cellular uptake capacity of the dual-targeted platform, and the significant reduction in uptake upon combined receptor blockade substantiated the specificity conferred by RGD/FA dual targeting. In vivo SPECT imaging and biodistribution data further corroborated its favorable tumor-homing ability. These findings indicate that 177Lu-labeled RGD/FA dual-targeted LNPs hold considerable promise as a tumor-targeted radioactive imaging-guided theranostic platform with potential for future therapy, providing a solid experimental foundation for further investigations toward integrated tumor theranostics.
Förderung
- China Institute of Atomic Energy
- the Director Fund Project of China Institute of Atomic Energy
Zitieren
APA
Xie, H., Xu, Q., Shi, H., Han, Y., Lu, Z., Fan, C., Liu, Z., & Li, F. (2026). Construction and Biological Evaluation of [177Lu]Lu-Labeled RGD/FA Dual-Targeted Lipid Nanoparticles for Tumor Imaging and Potential Theranostic Applications. Pharmaceutics, 18(11), 1482. https://doi.org/10.3390/pharmaceutics18111482
Vancouver
Xie H, Xu Q, Shi H, Han Y, Lu Z, Fan C, et al. Construction and Biological Evaluation of [177Lu]Lu-Labeled RGD/FA Dual-Targeted Lipid Nanoparticles for Tumor Imaging and Potential Theranostic Applications. Pharmaceutics. 2026;18(11):1482. doi:10.3390/pharmaceutics18111482
BibTeX
@article{Xie2026,
author = {Xie, Haozhan and Xu, Qianlong and Shi, Haojie and Han, Yi and Lu, Zhengzheng and Fan, Caiyun and Liu, Zihua and Li, Fenglin},
title = {Construction and Biological Evaluation of [177Lu]Lu-Labeled RGD/FA Dual-Targeted Lipid Nanoparticles for Tumor Imaging and Potential Theranostic Applications},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1482},
doi = {10.3390/pharmaceutics18111482}
}
EUVIMED